# US 2021/0330626 A1 · Pharmaceutical composition for treating kidney cancer and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330626 A1
- Document ID: US20210330626A1
- Status: Published application
- Kind: A1
- Application number: 15/734,105
- Filed: 2019-05-31
- Published: 2021-10-28
- Earliest claimed: 2018-06-01
- Assignees: Sichuan Jiuzhang Biological Science and Technology Co., Ltd.
- Applicants: Sichuan Jiuzhang Biological Science and Technology Co., Ltd.
- Inventors: Jie ZHANG; Xiaoguang CHEN; Wang HUANG; Ya ZHANG
- Web page: https://patentgrep.com/patent/US20210330626A1

## CPC

- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition contains chlorogenic acid and coumaroyl quinic acid. The combined use of chlorogenic acid and coumaroyl quinic acid at a certain ratio can generate a synergistic enhancing effect to effectively inhibit the growth of human kidney cancer cell strain A479, rat kidney cell strain RuCa, and rat transplanted tumor RuCa, providing a novel choice for clinical treatment of kidney cancer and having good market application prospects.

## Claims

### Claim 1

A pharmaceutical composition, that includes chlorogenic acid and coumaroylquinic acid.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, characterized in that the mass ratio of chlorogenic acid to coumaroylquinic acid is 100:0.01-10.

### Claim 3 (depends on 2)

The pharmaceutical composition according to claim 2, characterized in that the mass ratio of chlorogenic acid to coumaroylquinic acid is 100:0.01-1.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, characterized in that said pharmaceutical composition includes chlorogenic acid, coumaroylquinic acid and targeted drugs.

### Claim 5 (depends on 4)

The pharmaceutical composition according to claim 4, characterized in that said targeted drug is selected from one of sorafenib, sunitinib and pazopanib.

### Claim 6 (depends on 4)

The pharmaceutical composition according to claim 4, characterized in that the mass ratio of chlorogenic acid, coumaroylquinic acid and targeted drug is 100:0.01-1:0.1-1.

### Claim 7 (depends on 1)

A pharmaceutical preparation, characterized in that it is prepared by using the pharmaceutical composition according to claim 1 as an active ingredient, with addition of pharmaceutically acceptable excipients.

### Claim 8 (depends on 7)

The preparation according to claim 7, characterized in that said preparation is an oral preparation or an injection preparation.

### Claim 9 (depends on 7)

The pharmaceutical preparation according to claim 7, characterized in that said excipients are selected from one or more of starch, β-cyclodextrin, dextrin, carbomer, microcrystalline cellulose, hydroxypropylmethyl cellulose, low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, polyethylene glycol (PEG), sodium carboxymethyl cellulose, methyl cellulose, ethyl cellulose, mannitol, sodium lauryl sulfate, croscarmellose sodium, lactose, glucose, vitamins, glutathione, folic acid, polyvinylpyrrolidone (PVP), cross-linked polyvinylpyrrolidone, magnesium stearate, talc, colloidal silicon dioxide, aspartame, orange flavor, sodium bisulfite, sodium bicarbonate, sodium carbonate, and enteric coating powder.

### Claim 10 (depends on 1)

The use of the pharmaceutical composition according to claim 1 in the preparation of a drug for treatment of kidney cancer.
